- ISIN
- US4622221004
- CUSIP
- 462222100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 17, 1991
Highlights
- Market Cap
- $8.60B
- Enterprise Value
- $9.87B
- EPS (TTM)
- -$3.46
- Total Revenue (TTM)
- $873.76M
- Gross Profit (TTM)
- $857.70M
- EBITDA (TTM)
- $4.33B
- Year Range
- $40.03 - $86.74
- Target Price
- $94.08
- ROA (TTM)
- -18.86%
- ROE (TTM)
- -128.44%
- Avg. Volume (1M)
- 5M
- Avg. Volume Value (1M)
- $272.86M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IONS Performance Chart
Ionis Pharmaceuticals, Inc. (IONS) is down 34.6% since the beginning of the year. At $52 per share, IONS is trading 40.3% below its 52-week high of $87. Investors who bought $1,000 worth of IONS shares 5 years ago would now be looking at an investment worth $1,394.
Loading charts...
Compare this symbol against anything
Returns By Period
Ionis Pharmaceuticals, Inc. (IONS) has returned -34.56% so far this year and 20.31% over the past 12 months. Over the last ten years, IONS has returned 3.21% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Ionis Pharmaceuticals, Inc.
- 1D
- -2.83%
- 1M
- -36.71%
- 6M
- -37.38%
- YTD
- -34.56%
- 1Y
- 20.31%
- 3Y*
- 7.90%
- 5Y*
- 6.87%
- 10Y*
- 3.21%
- ALL TIME*
- 5.06%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
IONS Monthly Returns History
Based on dividend-adjusted daily data since May 17, 1991, IONS's average daily return is +0.10%, while the average monthly return is +1.84%. At this rate, an investment would double in approximately 3.2 years.
Historically, 49% of months were positive and 51% were negative. The best month was Nov 1992 with a return of +91.7%, while the worst month was Dec 1999 at -59.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.
On a daily basis, IONS closed higher 47% of trading days. The best single day was Aug 22, 2001 with a return of +47.7%, while the worst single day was Dec 15, 1999 at -63.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.50% | -1.84% | -7.47% | -0.44% | 2.33% | 3.65% | -34.71% | -34.56% | |||||
| 2025 | -8.75% | 4.04% | -9.10% | 1.79% | 9.12% | 17.91% | 8.78% | -0.80% | 53.44% | 13.57% | 11.35% | -4.38% | 126.29% |
| 2024 | 1.58% | -12.03% | -4.11% | -4.82% | -8.94% | 26.86% | 3.78% | -3.60% | -15.98% | -4.17% | -6.93% | -2.16% | -30.90% |
| 2023 | 5.56% | -9.96% | -0.45% | -1.04% | 15.63% | 0.32% | 0.97% | -2.80% | 12.64% | -2.40% | 11.75% | 2.26% | 33.94% |
| 2022 | 4.50% | 4.97% | 10.96% | -0.76% | -0.65% | 1.37% | 1.46% | 13.21% | 4.02% | -0.07% | -7.71% | -7.40% | 24.12% |
| 2021 | 6.24% | -12.77% | -14.20% | -4.76% | -13.01% | 7.09% | -6.89% | 7.05% | -15.64% | -4.98% | -16.85% | 14.83% | -46.18% |
Benchmark Metrics
Ionis Pharmaceuticals, Inc. has an annualized alpha of 14.19%, beta of 1.09, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since May 17, 1991.
- This stock participated in 144.73% of S&P 500 Index downside but only 134.59% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 14.19%
- Beta
- 1.09
- R²
- 0.10
- Upside Capture
- 134.59%
- Downside Capture
- 144.73%
Return for Risk
Risk / Return Rank
IONS ranks 60 for risk / return — above 60% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Ionis Pharmaceuticals, Inc. (IONS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IONS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.03 | ||
| Sortino ratioReturn per unit of downside risk | -0.99 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.25 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.51 | 2.00 | -1.49 |
| Martin ratioReturn relative to average drawdown | 1.64 | 8.49 | -6.86 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Ionis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ionis Pharmaceuticals, Inc. was 91.42%, occurring on Mar 18, 2003. Recovery took 2597 trading sessions.
The current Ionis Pharmaceuticals, Inc. drawdown is 40.15%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-91.42%Mar 2003 | 3y 11d | 10y 3mo | 13y 4moMar 2000 - Jul 2013 | — |
-84.12%Nov 1994 | 3y | 1y 7mo | 4y 7moNov 1991 - Jun 1996 | — |
-76.00%Dec 1999 | 3y 6mo | 2mo 12d | 3y 8moJun 1996 - Mar 2000 | — |
-73.25%Jun 2016 | 1y 3mo | 2y 8mo | 3y 12moMar 2015 - Mar 2019 | — |
-70.39%Apr 2025 | 6y 1d | 10mo 4d | 6y 10moApr 2019 - Feb 2026 | 2025 selloff2025 |
Drawdown Indicators
| IONS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.42% | -56.78% | -34.64% |
Max Drawdown (1Y)Largest decline over 1 year | -40.15% | -9.10% | -31.05% |
Max Drawdown (3Y)Largest decline over 3 years | -52.36% | -18.90% | -33.46% |
Max Drawdown (5Y)Largest decline over 5 years | -52.36% | -25.43% | -26.93% |
Max Drawdown (10Y)Largest decline over 10 years | -70.39% | -33.92% | -36.47% |
Current DrawdownCurrent decline from peak | -40.15% | -1.58% | -38.57% |
Average DrawdownAverage peak-to-trough decline | -52.26% | -10.70% | -41.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.53% | 2.14% | +10.39% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Ionis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Ionis Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IONS relative to other companies in the Biotechnology industry. Currently, IONS has a P/S ratio of 9.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IONS in comparison with other companies in the Biotechnology industry. Currently, IONS has a P/B value of 19.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IONS
Add Ionis Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IONS